StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Chandan Taparia, Motilal Oswal

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))24 Jul 2026via LiveMint Markets

Entry₹1,954Inferred
Target₹2,070
Total upside +5.94% (call closed)
Stop loss₹1,890-3.28% risk
At expiry₹1,9516 Aug 2026, 3:30 pm
Expired-0.15%auction close
Follow Chandan Taparia for new calls(30% target hit, 259 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Aug 2026
5 supporting2 neutral1 opposing
Supports the BUY call (5)

Sun Pharma has received approval to manufacture and market semaglutide in Brazil, indicating a potential market expansion and new product offering.

BSE · Company Update·29 Jul · 1w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jul · 1w ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·29 Jul · 1w ago

Sun Pharma announced that Organon shareholders have approved the proposed acquisition, moving forward the company's strategic expansion plans.

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)

Sun Pharmaceutical Industries Limited has received approval to manufacture and market a generic version of semaglutide in South Africa, expanding its product portfolio and market access.

NSE · Press Release·15 Jul · 3w ago

(opens in new tab)
Neutral / worth noting (2)

CRISIL has removed the 'Rating Watch with Developing Implications' status and reaffirmed Sun Pharma's long-term bank facilities rating at 'CRISIL AAA/Stable'.

BSE · Company Update·5 Aug · yesterday

(opens in new tab)

Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27

NSE · Outcome of Board Meeting·31 Jul · 6d ago

(opens in new tab)
Weighs against the BUY call (1)

Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan

NewsGoogle News·23 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Chandan Taparia, Motilal Oswal

Every call and its outcome